Interleukin 17a antibody (PerCP-Cy5.5)

Catalog No. ABIN2660445

Product Details anti-Interleukin 17a Antibody (PerCP-Cy5.5)

Target: Interleukin 17a (IL17A) (Interleukin 17A (IL17A))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This Interleukin 17a antibody is conjugated to PerCP-Cy5.5

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.

Clone: TC11-18H10-1

Isotype: IgG1 kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Protect from prolonged exposure to light. Do not freeze.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for Interleukin 17a

Target: Interleukin 17a (IL17A) (Interleukin 17A (IL17A))

Alternative Name: IL-17A (IL17A Products)

Background: IL-17, also known as CTLA-8, is a T cell-expressed pleiotropic cytokine that exhibits a high degree of homology to a protein encoded by the ORF13 gene of herpes virus Saimiri. IL-17 is produced by Th cells (Th17) that are distinct from the traditional Th1- and Th2-cell subsets. IL-23 plays an important role in triggering IL-17 production. Both recombinant and natural IL-17 have been shown to exist as disulfide linked homodimers. IL-17 exhibits multiple biological activities on a variety of cells including: the induction of IL-6 and IL-8 production in fibroblasts, activation of NF-κB, and costimulation of T cell proliferation. IL-17 is an essential inflammatory mediator in the development of autoimmune diseases. Neutralization of IL-17 with monoclonal antibody is able to ameliorate the disease course.